Company / R&D Expense
ADMA Biologics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$4.8M
FY2025
5-year range
$1.5M / $4.8M
FY2021-FY2025
Trend
+162.7%
vs FY2024
Sector context
#206 of 210
Health Care
What the data says
Among 210 Health Care companies, ADMA Biologics, Inc. is in the bottom 2% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $1M in FY2019 to $8M in FY2017.
Based on SEC 10-K filings.
$5M in FY2025 with a 5-year CAGR of -4.2%.
Improved from $3M to $5M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +47.0%
- 5-Year CAGR
- -4.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 210This company $4.8M Sector average $644.0M
▼
-99.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -4.2%, indicating a declining trend.
- In FY2025, r&d expense increased 162.7% year-over-year.
- Ranks #206 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.8M | +162.7% |
| FY2024 | $1.8M | -45.1% |
| FY2023 | $3.3M | +120.0% |
| FY2022 | $1.5M | -58.9% |
| FY2021 | $3.6M | -38.3% |
| FY2020 | $5.9M | +490.7% |
| FY2019 | $1.0M | -74.5% |
| FY2018 | $3.9M | -48.9% |
| FY2017 | $7.7M | +0.0% |
| FY2016 | $7.7M | -19.2% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026